PMID- 15340373
OWN - NLM
STAT- MEDLINE
DCOM- 20041018
LR  - 20230917
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 91 Suppl 2
IP  - Suppl 2
DP  - 2004 Aug
TI  - Treatment of non-small-cell lung cancer: a perspective on the recent advances and 
      the experience with gefitinib.
PG  - S11-7
AB  - Worldwide, non-small-cell lung cancer (NSCLC) is a leading cause of 
      cancer-related mortality and, until screening detects early disease, treatment 
      for the majority of patients will consist of radiation therapy, chemotherapy or 
      combinations thereof. Modern mono and doublet chemotherapy regimens have 
      translated into modest increases in life expectancy and improved quality of life, 
      but at the expense of systemic and pulmonary adverse events (AEs). There is a 
      great unmet need to provide effective therapy for advanced NSCLC that does not 
      have the toxicity burden of conventional chemotherapy and radiotherapy. Novel 
      drugs that inhibit a range of growth factor receptors, such as the epidermal 
      growth factor receptor tyrosine kinase inhibitors gefitinib ('Iressa') and 
      erlotinib ('Tarceva') or the monoclonal antibody cetuximab ('Erbitux'), have 
      recently been evaluated. Having demonstrated antitumour activity and rapid 
      symptom improvement in pretreated patients with advanced NSCLC, gefitinib was 
      approved in the USA, Japan and other countries. Gefitinib is well tolerated with 
      a low incidence of grade 3/4 AEs. Interstitial lung disease has been reported in 
      a small number of patients receiving gefitinib, although this may be attributed 
      to other treatments and conditions. Nevertheless, although the use of novel 
      treatments requires vigilance for unexpected AEs such as pulmonary toxicity, in 
      this area of high unmet clinical need, the benefits outweigh the risks in 
      patients for whom no other proven effective treatment exists.
FAU - Onn, A
AU  - Onn A
AD  - Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD 
      Anderson Cancer Center, Box 403, 1515 Holcombe Boulevard, Houston, TX 77030-4009, 
      USA. amironn@mdanderson.org
FAU - Tsuboi, M
AU  - Tsuboi M
FAU - Thatcher, N
AU  - Thatcher N
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Antimetabolites, Antineoplastic/adverse effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Clinical Trials as Topic
MH  - Deoxycytidine/adverse effects/*analogs & derivatives/*therapeutic use
MH  - Health Status
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Middle Aged
MH  - Gemcitabine
PMC - PMC2750809
EDAT- 2004/09/02 05:00
MHDA- 2004/10/19 09:00
PMCR- 2005/08/31
CRDT- 2004/09/02 05:00
PHST- 2004/09/02 05:00 [pubmed]
PHST- 2004/10/19 09:00 [medline]
PHST- 2004/09/02 05:00 [entrez]
PHST- 2005/08/31 00:00 [pmc-release]
AID - 6602062 [pii]
AID - 10.1038/sj.bjc.6602062 [doi]
PST - ppublish
SO  - Br J Cancer. 2004 Aug;91 Suppl 2(Suppl 2):S11-7. doi: 10.1038/sj.bjc.6602062.